BAT2206

BAT2206 is a proposed biosimilar to Janssen's Stelara® (ustekinumab). It is a human monoclonal antibody that inhibits the bioactivity of human IL-12 and IL-23 by preventing shared p40 from binding to the IL-12Rβ1 receptor protein expressed on the surface of immune cells. IL-12 and IL-23 are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. These cytokines have been implicated as important contributors to chronic inflammation in conditions like Crohn's disease, ulcerative colitis, and other autoimmune diseases. BAT2206 is developed by Bio-Thera Solutions using recombinant DNA technology and expressed in a mammalian Chinese hamster ovary cell system.

Other names

ustekinumab biosimilar